| Chairs: Joel Buxbaum, La Jolla, CA, USA Violaine Plante-Bordeneuve, Créteil, France |
|
| ATTR AMYLOIDOSIS | |
| OP 08 | Long-term safety and efficacy of patisiran: Global open-label extension 24-month data in patients with hereditary transthyretin-mediated amyloidosis David Adams, Le Kremlin Bicêtre, France |
| OP 09 | Long-term impact of tafamidis in patients with late-onset hereditary transthyretin amyloidosis with stage I polyneuropathy Roberta Mussinelli, Pavia, Italy |
| OP 10 | External validation of the national amyloidosis center score in an international cohort of patients with transthyretin cardiac amyloidosis Adrián Rivas-Pérez, Madrid, Spain |
| OP 11 | Evaluation of patisiran with concomitant or prior use of transthyretin stabilizers in patients with hereditary transthyretin-mediated amyloidosis Hollis Lin, Cambridge, MA, USA |
| OP 12 | Open-label study of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy post-orthotopic liver transplant Julian Gillmore, London, UK |
| OP 13 | High resolution nerve ultrasound as a diagnostic tool for differential diagnosis and progression recognition in TTR-related familial amyloidosis Natalie Winter, Tübingen, Germany |
| OP 14 | Origin of val30met in familial amyloid polyneuropathy (TTR-FAP) in Portugal: a walk through the mutational path Carolina Lemos, Porto, Portugal |
| OP 15 | 99mTc-DPD scintigraphy predicts amyloid fibril type in hereditary transthyretin amyloidosis Jonas Wixner, Umeå, Sweden |
| 14:56 – 15:30 | Discussion |
| Multidisciplinary treatment approach in the management of patients with AL amyloidosis Chair: Giovanni Palladini, Pavia, Italy Diagnostic pit-falls and risk stratification in AL amyloidosis Efstathios Kastritis, Athens, Greece Monoclonal antibody treatment for AL amyloidosis Ashutosh Wechalekar, London, UK Novel targets and drugs for AL amyloidosis Giovanni Palladini, Pavia, Italy |
| Experts’ discussion on the Treatment of Patients with AL Amyloidosis non-eligible for ASCT: burning questions Chair: Morie A. Gertz, Rochester, MN, USA Panelists: Shaji Kumar, Rochester, MN, USA Monique C. Minnema, Utrecht, the Netherlands Paolo Milani, Pavia, Italy Maria Teresa Cibeira, Barcelona, Spain Arnaud Jaccard, Limoges, France Maria Gavriatopoulou, Athens, Greece Topics: • Best initial therapy for fit patients • Best inicial therapy for unfit patients • When to start therapy at relapse or progression • Treatment at first relapse • Treatment at later relapses or refractory disease • Best novel emerging agents • Role of anti-amyloid therapy |
| Chairs: Matthias Schmidt, Ulm, Germany Francesca Lavatelli, Pavia, Italy |
|
| BASIC SCIENCE II | |
| OP16 | Hepatic expression of mutant transthyretin remodels proteostasis machinery in hereditary ATTR amyloidosis Richard Giadone, Boston, MA, USA |
| OP17 | Diagnostic potential of a novel RT-QPCR-based assay to measure CCND1 MRNA expression levels in bone marrow plasma cells from al amyloidosis patients Alice Nevone, Pavia, Italy |
| OP18 | Machine learning predicts immunoglobulin light chain toxicity through somatic mutations Maura Garofalo, Bellinzona, Switzerland |
| OP19 | Drosophila melanogaster as a model organism for ATTR amyloidosis Xiaohong Gu, Uppsala, Sweden |
| OP20 | Eleven different amyloid types identified in cutaneous amyloidosis by proteomics-based typing Surendra Dasari, Rochester, MN, USA |
| 19:05 - 19:20 | Discussion |